Robert H Vonderheide Selected Research

selicrelumab

1/2021	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
1/2014	Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
11/2013	A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
1/2013	Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
11/2010	Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.
11/2009	Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
3/2007	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert H Vonderheide Research Topics

Disease

125	Neoplasms (Cancer) 04/2024 - 01/2002
24	Pancreatic Neoplasms (Pancreatic Cancer) 04/2024 - 06/2012
18	Adenocarcinoma 02/2024 - 05/2013
12	Melanoma (Melanoma, Malignant) 01/2023 - 03/2003
11	Breast Neoplasms (Breast Cancer) 01/2023 - 03/2005
7	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2019 - 11/2006
5	Carcinoma (Carcinomatosis) 11/2017 - 02/2004
4	Carcinogenesis 05/2014 - 02/2004
3	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 11/2006
3	Mesothelioma 01/2020 - 03/2005
3	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 11/2006
3	Infections 01/2017 - 02/2007
3	Neuroblastoma 11/2009 - 03/2004
2	Fatigue 01/2022 - 01/2021
2	COVID-19 01/2022 - 01/2021
2	Nausea 01/2021 - 01/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2019 - 03/2005
2	Disease Progression 01/2018 - 12/2016
2	Neoplasm Metastasis (Metastasis) 01/2016 - 03/2003
2	Inflammation (Inflammations) 06/2012 - 04/2011
2	Human Influenza (Influenza) 01/2011 - 06/2003
2	Multiple Myeloma 01/2011 - 06/2003
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2011 - 09/2003
2	Pleural Effusion (Pleural Effusions) 04/2010 - 03/2005
2	Malignant Pleural Effusion 04/2010 - 03/2005
1	Vitamin D Deficiency 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Septic Shock (Toxic Shock Syndrome) 01/2021
1	Vomiting 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021

Drug/Important Bio-Agent (IBA)

22	AntigensIBA 01/2021 - 01/2002
14	Monoclonal AntibodiesIBA 02/2024 - 03/2007
14	VaccinesIBA 01/2022 - 03/2003
13	Peptides (Polypeptides)IBA 11/2023 - 01/2002
13	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2023 - 01/2002
12	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
12	AntibodiesIBA 02/2021 - 03/2003
10	CytokinesIBA 01/2022 - 09/2003
10	Proteins (Proteins, Gene)FDA Link 12/2021 - 06/2002
7	selicrelumabIBA 01/2021 - 03/2007
7	EnzymesIBA 01/2013 - 01/2002
6	NivolumabIBA 01/2022 - 01/2015
6	Neoplasm Antigens (Tumor Antigens)IBA 12/2008 - 01/2003
5	LigandsIBA 12/2021 - 01/2013
5	Gemcitabine FDA Link 01/2021 - 03/2011
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020 - 03/2003
5	EpitopesIBA 08/2009 - 06/2002
4	RNA (Ribonucleic Acid)IBA 01/2023 - 09/2003
4	pembrolizumabIBA 11/2018 - 01/2015
3	Biomarkers (Surrogate Marker)IBA 02/2024 - 12/2016
3	IpilimumabIBA 01/2022 - 01/2015
3	Immunoglobulin G (IgG)IBA 02/2021 - 03/2003
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2007
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 07/2010
3	Maraviroc FDA Link 01/2019 - 07/2015
3	Chimeric Antigen ReceptorsIBA 01/2018 - 07/2015
3	Interferon-gamma (Interferon, gamma)IBA 12/2016 - 02/2007
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 03/2013 - 02/2007
3	Cancer VaccinesIBA 05/2012 - 06/2004
3	SurvivinIBA 12/2008 - 03/2004
2	Transcription Factors (Transcription Factor)IBA 02/2024 - 01/2018
2	PlatinumIBA 01/2022 - 01/2021
2	sotigalimabIBA 01/2022 - 01/2021
2	Messenger RNA (mRNA)IBA 12/2021 - 12/2017
2	Immunoglobulin M (IgM)IBA 02/2021 - 03/2012
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2020
2	130-nm albumin-bound paclitaxelIBA 01/2021 - 01/2016
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 12/2013
2	PerforinIBA 01/2021 - 01/2019
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2018
2	olaparibIBA 01/2021 - 01/2021
2	rucaparibIBA 01/2021 - 01/2018
2	Chemotactic FactorsIBA 01/2020 - 01/2013
2	ChemokinesIBA 01/2020 - 11/2017
2	Hormones (Hormone)IBA 01/2019 - 07/2010
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019 - 01/2013
2	InterferonsIBA 12/2016 - 11/2006
2	Daclizumab (Zenapax)FDA Link 05/2012 - 09/2009
2	Interferon-betaIBA 04/2010 - 11/2006
2	telomerase reverse transcriptase (540-548)IBA 12/2007 - 02/2004
2	AutoantigensIBA 11/2005 - 02/2004
2	HLA-A*02:01 antigenIBA 06/2003 - 06/2002
1	Guanosine Triphosphate (GTP)IBA 04/2024
1	Interferon Regulatory FactorsIBA 02/2024
1	KRASG12D inhibitor MRTX1133IBA 01/2023
1	Vitamin D FDA LinkGeneric 01/2022
1	niraparibIBA 01/2022
1	3,3',4',5-tetrachlorosalicylanilideIBA 12/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021
1	SteroidsIBA 01/2021

Therapy/Procedure

59	Immunotherapy 02/2024 - 01/2002
49	Therapeutics 04/2024 - 01/2002
17	Drug Therapy (Chemotherapy) 01/2023 - 09/2003
6	Hematopoietic Stem Cell Transplantation 01/2018 - 08/2009
4	Radiotherapy 01/2021 - 01/2018
3	Cell Transplantation 01/2022 - 09/2003
3	Adjuvant Chemotherapy 01/2021 - 04/2010
2	Stem Cell Transplantation 01/2011 - 08/2009
2	Intravenous Infusions 11/2010 - 09/2009